Chfr is a ubiquitin ligase that functions in the mitotic checkpoint by delaying entry into metaphase in response to mitotic stress 1,2 . It has been suggested that Chfr is a tumour suppressor as Chfr is frequently silenced in human cancers 3 . To better understand how Chfr activity relates to cell-cycle progression and tumorigenesis, we sought to identify Chfr-interacting proteins using affinity purification combined with mass spectrometry. Histone deacetylase 1 (HDAC1), which represses transcription by deacetylating histones, was newly isolated as a Chfr-interacting protein. Chfr binds and downregulates HDAC1 by inducing its polyubiquitylation, both in vitro and in vivo. Ectopic expression of Chfr in cancer cells that normally do not express it results in downregulation of HDAC1, leading to upregulation of the Cdk inhibitor p21 CIP1/WAF1 and the metastasis suppressors KAI1 and E-cadherin. Coincident with these changes, cells arrest in the G1 phase of the cell cycle and become less invasive. Collectively, our data suggest that Chfr functions as a tumour suppressor by regulating HDAC1.
, we investigated whether HDAC2 can bind Chfr. HDAC2 was co-immunoprecipitated with Chfr, whereas other HDACs, such as HDAC3 or HDAC4, were not detected in Chfr immunoprecipitates. However, other components of HDAC1-containing complexes, such as SIN3A, were detected in Chfr immunoprecipitates when large amounts of Chfr immunoprecipitaes were subjected to immunoblot analysis ( Supplementary Information,  Fig. S2 ). Thus, this result indicates that Chfr-HDAC1 may form a subset of HDAC1-containing complexes.
We mapped the region of Chfr required for its interaction with HDAC1. Flag-tagged deletions of Chfr were generated ( Fig. 2a) and co-expressed with Myc-HDAC1. Western blot analysis of Flag-Chfr immunoprecipitates revealed that the carboxy-terminal cysteine-rich (CR) region of Chfr is required for its interaction with HDAC1 (Fig. 2b) . It has been reported that the kinase Aurora A interacts with the CR region of Chfr, whereas the kinase Plk1 interacts with the forkhead-associated (FHA) domain 1, 2, 9, 10 . Competition binding assays showed that the kinase Aurora A, but not Plk1, competed with HDAC1 for binding to Chfr (Fig. 2c) . Next, we mapped the region of HDAC1 that is responsible for its interaction with Chfr. The C-terminal region of the HDAC1 deacetylase domain seems to be involved in its interaction with Chfr ( Supplementary Information, Fig. S3 ). As, out of the HDAC proteins, only HDAC1 and HDAC2 can bind to Chfr directly, we aligned the amino acid sequences of the putative Chfr-binding region in the class I HDACs. The amino acids Phe 287 and Met 297, which are conserved in HDAC1 and HDAC2, were replaced with Tyr and Ile respectively, to generate the mutant HDAC1 FM . Chfr was immunoprecipitated with wild-type HDAC1 (HDAC1 WT ) but not HDAC1 FM (Fig. 2d ). Although HDAC1
FM did not interact with Chfr, it was fully functional as a deacetylase ( Supplementary Information, Fig. S6 ). These results indicate that Phe 287 and Met 297 of HDAC1 are not important for its deacetylase activity, but are crucial for its interaction with Chfr.
l e t t e r s
To determine the functional consequence of the Chfr-HDAC1 interaction, we tested whether Chfr affects cellular levels of HDAC1. We found that HDAC1 accumulation varied inversely with levels of cotransfected Chfr (Fig. 3a) . Co-expression of Chfr I306A and Chfr lacking a CR region (Chfr ∆CR ) did not antagonize accumulation of HDAC1, indicating that both the substrate-and E2 (ubiquitin conjugating enzyme)-binding domains of Chfr are required for this effect (Fig. 3b) . Moreover, Chfr-dependent loss of HDAC1 was blocked by the proteasome inhibitor MG132. Most importantly, expression of Chfr downregulated endogenous HDAC1 ( Supplementary Information, Fig. S5 ) by increasing its rate of degradation, as measured in a cycloheximide-chase assay (Fig. 3c) . Together, these results suggest that the ubiquitin ligase activity of Chfr targets HDAC1 for degradation. Chfr-dependent turnover was specific, in that HDAC2 was also antagonized by co-expressed Chfr, but the levels of HDAC proteins that did not bind Chfr (HDAC3 and HDAC1 FM ) were unchanged. During the course of these studies, we noted that the Chfr I306A mutant accumulated to a higher level than HDAC1 WT and Chfr ΔCR , suggesting that the cellular level of Chfr may be controlled by auto-ubiquitylation.
To investigate whether endogenous Chfr contributes to the regulation of HDAC1, we depleted HEK293T cells, of endogenous Chfr using RNA interference (RNAi). Analysis by reverse transcription-PCR (RT-PCR) confirmed both the specificity and efficacy of our short hairpin Chfr construct (shChfr). Importantly, the level of HDAC1 was increased when Chfr was silenced (Fig. 3d) . These results indicate that Chfr regulates the levels of endogenous HDAC1 by controlling its degradation.
Chfr possesses ubiquitin ligase activity, which suggests that Chfr mediates proteasome-dependent turnover of HDAC1 by directly ubiquitylating it. To determine whether HDAC1 can be ubiquitylated by Chfr in vitro, Flag-HDAC1 expressed in HeLa cells and His-Chfr or His-Chfr I306A expressed in insect cells were purified. HDAC1 was ubiquitylated in a Chfr-dependent manner (Fig. 3e) (Fig. 3f) . By contrast, little or no ubiquitylation of HDAC1 was observed in the absence of Chfr or when it was co-expressed with Chfr I306A or Chfr ∆CR . Notably, ubiquitylation of endogenous HDAC1 was decreased in HEK293T cells depleted of endogenous Chfr by shChfr ( Supplementary Information, Fig. S5 ). Despite the major effect of Chfr on the ubiquitylation status of HDAC1, total cellular ubiquitin conjugates were not affected by either over-expression or depletion of Chfr. Taken together, these results indicate that Chfr ubiquitylates HDAC1 that is bound to its CR domain, resulting in proteasomal degradation of HDAC1.
HDAC1 is a histone deacetylase that has a crucial role in controlling the expression of genes required for cell-cycle progression and tumour metastasis 11, 12 . To determine the relationship between Chfr and HDAC1 Purified Flag-Chfr and GST-HDAC1 or GST was incubated with glutathione Sepharose for 1 h at 4 °C. Precipitates were subjected to SDS-PAGE followed by immunoblotting with anti-Flag or anti-GST antibodies.
function, we first evaluated whether the deacetylase activity of HDAC1 contributes to its turnover by Chfr. HDAC1 H141A , a mutant that lacks deacetylase activity 13 , was transiently expressed in HeLa cells along with Chfr. Immunoprecipitation and western blot analysis revealed that HDAC1 H141A bound to (Fig. 3g) and was destabilized by, Chfr (Fig. 3h ), suggesting that Chfr can promote turnover of HDAC1 regardless of HDAC1's activity.
To explore the effect of turnover on HDAC1 function, we examined the effect of gain-or loss-of-function of Chfr on HDAC1-dependent transcriptional regulation. A vector encoding HAT(p300) was cotransfected with (Fig. 4a) . As it was reported that HDAC1 also deacetylates non-histone proteins 14 , we evaluated the effects of Chfr on p53 deacetylation. HAT(p300)-stimulated acetylation of p53 was diminished by HDAC1, but this decline was also reversed by Chfr ( Supplementary Information, Fig. S6 ). These results suggest that Chfr controls the deacetylase activity of HDAC1 towards both histone and non-histone proteins.
Given that Chfr-mediated degradation of HDAC1 modulates acetylation of HDAC1 substrates, we next examined whether Chfr derepresses genes regulated by HDAC1. Transcription of p21 is inhibited by HDAC1 activity 15 . Real-time PCR (rtPCR; Fig. 4b ) and RT-PCR (Fig. 4c) revealed that the amount of p21 mRNA was increased on expression of Chfr, whereas the Chfr I306A mutant had no effect. Similarly, the level of the endogenous p21 protein was increased on expression of Chfr but not Chfr I306A . The role of HDAC1 in cellular function is very complex. HDAC inhibitors arrest the cell cycle in the G1 or G2 phase 15, 16 . In the absence of HDAC1, cells arrest either in the G1 phase or at the G2-M phase transition, resulting in loss of mitotic cells, cell growth inhibition and an increase in the percentage of apoptotic cells 17 . As our data suggest that Chfr promotes p21 gene expression by downregulating HDAC1, we examined the effect of Chfr expression on cell-cycle progression.
HeLa cells transfected with Flag-Chfr were cultured for various times and subjected to FACS (fluorescence-activated cell sorting) analysis to determine their DNA content (Fig. 4f) . The fraction of cells in G1 and the level of p21 were significantly increased by 48 h in culture. Consistent with the hypothesis that Chfr expression arrests cells in G1, immunofluorescence confirmed that cells expressing Flag-Chfr contained little or no phospho-histone H3 and cyclin B after 48 h in culture (Fig. 4f) . Both the fraction of G1-phase cells and p21 levels decreased at later timepoints, probably owing to an increase in the number of cells that were not transfected with Flag-Chfr, as Chfr levels also decreased at 72 h. these results suggest that Chfr over-expression causes p21-dependent cell-cycle arrest in G1 and that Chfr may contribute to checkpoint function during interphase of the cell cycle as well as during mitosis.
To further clarify the physiological role of Chfr in p21 gene expression, HEK293T cells transfected with either shChfr or a control vector, were irradiated with ionizing radiation (IR), incubated for various periods and subjected to real-time PCR. After exposure to IR for 24 h, the transcription level of p21 showed an 8-fold increase in the control cells, but not in the shChfr cells (Fig. 4g) . Our results suggest that Chfr can regulate progression through different stages of the cell cycle by controlling the turnover of different proteins at each stage.
Although Chfr is ubiquitously expressed in normal tissues, it is frequently downregulated in human cancers 3 , mainly because of hypermethylation of its promoter region [18] [19] [20] . To address whether Chfr participates in tumour development, we assessed the expression level of Chfr and HDAC1 in human prostate (PC-3) or breast (MCF7) cancer cells. Whereas Chfr was expressed in normal, non-metastatic prostate (RWPE1) and breast (MCF10A) cells, little or no Chfr was observed in the metastatic PC-3 and MCF7 cancer cells. Interestingly, the levels of HDAC1, Plk1 and Aurora A, all potential substrates of Chfr, were much higher in metastatic cancer cells, compared with normal cells (Fig. 5a ). In addition to its role in p21 expression, HDAC1 may also have an important role in tumour metastasis through its ability to repress expression of the metastasis suppressor gene KAI1 (ref. 12) and the invasion suppressor gene E-cadherin 21, 22 . To evaluate whether Chfr could have a role in metastasis, we examined whether it influenced the expression of KAI1 or E-cadherin in metastatic cancer cells. using real-time PCR in MCF7 cells (which do not express endogenous Chfr) revealed that expression of both KAI1 and E-cadherin mRNA was markedly stimulated by Chfr. Consistent with increased transcription of KAI1 and E-cadherin, levels of the KAI1 and E-cadherin proteins were also elevated in cells expressing Chfr (Fig. 5b) . To determine the potential effect of Chfr and HDAC1 on metastatic capacity, we forced expression of Chfr or downregulated HDAC1 expression in MCF7 cells and evaluated the invasive activity of the cells in a Matrigel invasion assay 23 . Over-expression of Chfr, RNAimediated knockdown of HDAC1 or treatment with TSA decreased the FM and/or Flag-Chfr. After incubation for 24 h, cell lysates were analysed by immunoblotting with anti-Flag antibodies. Histones were purified as described previously 25 , and acetylated histone was detected by an anti-Acyl-H4 antibody. Uncropped images of the scans are shown in Supplementary Information, Fig. S8. (b, c) HeLa cells were transfected with 2 μg of empty, Chfr or Chfr I306A vector. After incubation for 48 h, total RNA was prepared. Real-time PCR (b) and RT-PCR (c) were carried out using specific primers for p21 and GAPDH mRNAs (mean ± s.d., n = 3). The corresponding cell lysates were subjected to SDS-PAGE followed by immunoblotting with the indicated antibodies. Uncropped images of the scans are shown in the Supplementary Information, Fig. S8. (d, e) Chfr relieves transcriptional repression on a p21-luciferase reporter. HeLa cells were transfected with the indicated vectors (d). After incubation for 48 h, luciferase activity was measured and normalized by β-galactosidase assay (e). Cells were treated for 2 h with TSA (5 μM) before assay (mean ± s.d., n = 3). (f) HeLa cells transfected with Flag-Chfr or an empty vector were cultured for the indicated times and subjected to FACS analysis to determine their DNA content. They were also subjected to immunoblot analysis with anti-Flag or anti-p21 antibodies. For immunocytochemistry, HeLa cells were transiently transfected with Flag-Chfr. After incubation for 48 h, cells were stained with anti-Flag (Chfr), anti-phospho-histone H3 or cyclin B antibodies. Scale bars represent 10 μm. (g) HEK293T cells were irradiated with IR (15 Gy) and incubated for the indicated times. Total RNA was prepared from cells and real-time PCR was then carried out using specific primers for p21 and GAPDH. l e t t e r s ability of MCF7 cells to invade Matrigel by approximately 60%, compared with control cells (Fig. 5c) . Furthermore, expression of HDAC1 FM or HDAC1
WT slightly increased the invasive activity of MCF7 cells, but this increase was reversed by treatment with TSA (Fig. 5d) . Conversely, co-expression of Chfr blocked the increase in invasiveness caused by expression of HDAC1 WT , but had no effect on invasiveness induced by expression of HDAC1 FM . Taken together, our data suggest that Chfr malfunction in cancer cells can lead to HDAC1 stabilization, which in turn blocks expression of metastasis suppressors, such as KAI1 and E-cadherin. To further determine whether endogenous Chfr could have a role in metastasis, we evaluated the invasive activity of HeLa cells that had been stably reconstituted with Chfr (HeLa-Chfr). The invasive activity of the HeLa-Chfr cells was about six times lower than that of HeLa cells (Fig. 5e) . Furthermore, in MCF10A cells, which naturally express endogenous Chfr, RNAi-mediated knockdown of Chfr increased the ability of cells to invade Matrigel, and this increase was partially reversed Supplementary  Information, Fig. S8 . l e t t e r s by shRNA-mediated depletion of HDAC1 ( Supplementary Information,  Fig. S7d ). These data suggest that endogenous Chfr affects metastasis, at least in part, by downregulating HDAC1. To strengthen the connection between Chfr-mediated HDAC1 downregulation and cell migration, we evaluated the invasive activity of HeLa or HeLa-Chfr cells, which stably expressed HDAC1 WT or HDAC1 FM (Fig. 5f ). HDAC1 FM is resistant to Chfr-mediated downregulation, and HDAC1 FM -expressing cells are resistant to Chfr-mediated reduction in cell migration. These data directly demonstrate that the observed changes in cell migration are caused by Chfr-mediated HDAC1 downregulation.
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Chfr was originally identified on the basis of its role in mediating cell-cycle checkpoint arrest triggered by mitotic stress 24 . In our study we found that Chfr mediates ubiquitylation and turnover of HDAC1, which is a key transcriptional regulator. HDAC1 could promote cancer by at least two distinct mechanisms: 1) repression of p21 expression, resulting in the loss of a p21-dependent G1 checkpoint, which arrests cells in the G1 phase in response to DNA damage, and 2) repression of metastasis suppressor gene expression, such as KAI1 and E-cadherin. We show here that forced expression of Chfr in cancer cells, in which its expression is normally extinguished, results in downregulation of HDAC1, upregulation of p21, KAI1 and E-cadherin and reduced invasiveness. Taken together, our data uncover a mechanism by which loss of Chfr activity could contribute to the development of human cancer.
METHODS
Cell culture and transfection. HEK293T, HeLa and MCF7 cells were grown at 37 °C in DMEM supplemented with 100 U ml -1 penicillin, 1 μg ml -1 streptomycin and 10% FBS. All transfections were carried out using LipofectaminePlus (Invitrogen).
Plasmids and antibodies.
Chfr complementary DNA (cDNA) was isolated from a human brain cDNA library and cloned into pcDNA-Myc, pcDNA4-HisMax, p3×Flag-CMV10 and pFastBac vector. Chfr-specific (shchfr) or HDAC1-specific (shHDAC1) shRNA were synthesized and cloned into pSilencer 2.0-U6 (Ambion). Target sequences for shRNAs were as follows: shChfr, 5´-AGAUACCUCAGGUGCAGGU-3´; shHDAC1, 5´-AAGCAGATGCAGAGATTCAAC-3´. Antibodies used for experiments were as follows: anti-Flag and β-actin (1:5000; Sigma); anti-acetylated histone H4, anti-cyclin B, anti-Plk1 and anti-E-cadherin (1:1000; Upstate Biotechnology); anti-HDAC1, anti-KAI1, anti-Myc and anti-HA (1:1000; Santa Cruz); anti-Xpress (1:5000; Invitrogen); anti-Aurora A and anti-Cyclin A (1:2000; Cell Signaling Technology); peroxidase-conjugated AffiniPure goat anti-rabbit and anti-mouse IgGs (1:5000; Bio-Rad); rabbit polyclonal anti-Chfr antiserum was raised against a recombinant His-Chfr (1:1000).
Assays for protein-protein interaction. Cells were lysed in buffer A consisting of 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EDTA and 0.2% Triton X-100 and a 1× protease inhibitor cocktail (Roche ). Cell lysates were incubated with anti-M2 resin (Sigma) or 9E10 resin for 2 h at 4 °C. The resins were collected by centrifugation, and then washed three times with buffer A and twice with buffer B, which consisted of 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1 mM EDTA. Bound proteins were eluted by 0.2% SDS and separated by SDS-PAGE, followed by staining with silver or immunoblotting with the appropriate antibodies.
To analyse the interaction of Chfr and HDAC1 in vitro, GST-HDAC1 was purified from E. coli cells and Flag-Chfr proteins were purified from HEK293T cells with anti-M2 resin. Purified Flag-Chfr (4 μg) and GST-HDAC1 (4 μg) were incubated with glutathione Sepharose for 1 h at 4 °C. The resins were washed three times with buffer A to remove Chfr not bound to HDAC1. Bound proteins were eluted using 0.2% SDS and subjected to SDS-PAGE followed by immunoblotting with appropriate antibodies.
To analyse competition between HDAC1, Plk1 and Aurora A for binding to Chfr in vitro, GST-HDAC1 (1 μg, purified from E. coli) and His-Chfr (1 μg, purified from insect cell) were incubated with increasing quantities of Flag-PLK1 or Flag-Aurora A (0.5, 1, 2 and 4 μg) for 1 h at 4 °C and pulled down by NTA resin. The resins were washed three times with buffer A to remove HDAC1, Plk1 and Aurora A not bound to Chfr. Precipitates of bound proteins were eluted with 0.2% SDS and subjected to SDS-PAGE followed by immunoblotting with the appropriate antibodies.
Assays for ubiquitylation and pulse-chase analysis. For in vitro ubiquitylation assays, purified Flag-HDAC1 (1 μg) from HeLa cells was incubated at 37 °C for the indicated times with E1 (0.5 μg), UbcH5b (0.5 μg), Ub (5 μg), ATPregenerating system (50 mM Tris-HCl pH 7.5, 5 mM MgCl 2 , 10 mM creatine phosphate, 5 U ml -1 of phosphocreatine kinase and 5 mM ATP) and 1× protease inhibitor cocktail in the presence or absence of His-Chfr (3 μg) purified from insect cells. After incubation, each sample was subjected to SDS-PAGE and immunoblotted with anti-Flag (HDAC1) antibody.
For in vivo ubiquitylation assays, HeLa cells were transfected with plasmids encoding Flag-HDAC1, HA-ubiquitin and Myc-Chfr (wild-type, I306A mutant or ∆CR mutant). After incubation for 24 h, cells were treated with MG132 (2 μM) for 12 h. Cells were lysed with buffer A and incubated with anti-M2 resin for 2 h at 4 °C. The resins were collected by centrifugation and washed three times with buffer A. The samples were then subjected to SDS-PAGE followed by immunoblotting analysis.
For pulse-chase analysis, HeLa cells that had been transfected with the appropriate vectors were cultured for 24 h. After incubation, the cells were treated with cycloheximide (200 μg ml -1 ) for 8 h. Cell lysates then were subjected to immunoblotting with the indicated antibodies.
Reporter assays. Luciferase activity was measured in a luminometer 48 h after transfection and normalized by β-galactosidase expression with a luciferase system (Promega). Values are expressed as mean ± s.d. for at least three independent experiments.
RT-PCR and real-time PCR. Total RNA was extracted from HEK293T and HeLa cells with Ultraspec (BioTex). Reverse transcription reactions were performed using RevertAid M-MuLV reverse transcriptase and oligo (dT) primer, according to the manufacturer's instructions. Real-time PCR was performed using platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and the 7300 real-time PCR system (Applied Biosystems). Chfr and p21 mRNA was amplified with primers against the unique region of Chfr and p21. GAPDH mRNA was amplified as an expression control. We used the following primers: p21
CIP1/WAF1
, forward, 5´-GCAGACCAGCATGACAGATTTC-3´; reverse, 5´-GGATTAGGGCTTCCTCTTGGA-3´; KAI1: forward, 5´-T TCTACT TCAACATGGGCAAGC-3´, reverse, 5´-AGGTGACCTCAGGGCGATTC-3´; E-cadherin: forward, 5´-TGAAGGTGACAGAGCCTCTGGAT-3´, reverse, 5´-TGGGTGAATTCGGGCTTGTT-3´. ). Propidium iodide-stained cells were then analysed for their DNA content by using a FACS instrument (BD Biosciences).
Immunocytochemistry. HeLa cells plated on gelatin-coated coverslips were fixed with 2% formaldehyde in PBS for 30 min at room temperature and permeabilized with 0.5% Triton X-100 in PBS. All subsequent dilutions and washes were performed with PBS containing 0.1% Triton X-100 (PBS-T). Non-specific binding sites were saturated by incubation for 30 min with a blocking solution consisting of 10% goat serum, 1% BSA and 1% gelatin in PBS. Cells were incubated with primary antibody for 1 h and washed with PBS-T four times at 10-min intervals. They were then incubated with FITC-or TRITC-conjugated secondary antibody for 1 h and washed four times. DAPI was used to counterstain the nuclei. The coverslips were mounted in Vectashield and cells were visualized under a Zeiss Axioplan II microscope.
Matrigel invasion assay. MCF7, MCF10A or HeLa cells were loaded into the top of a 24-well Matrigel invasion chamber assay plate (BD Biocoat). Conditioned HEK293T cells were transiently transfected with pCMV-3xFLAG as a control, pCMV-3xFLAG-Chfr-I306A and/or FLAG-HDAC1. cell lysates were immunoprecipitated with anti-M2 resin. Proteins co-immunoprecipitating with FLAG-Chfr-I306A and FLAG-HDAC1 were separated by SDS-PAGE, evaluated in parallel by immunoblotting with indicated antibodies. While HDAC2 was immunoprecipitated with Chfr, any components of HDAC complex such as SIN3A were not detected. (c) Chfr interacts with HDAC1 and HDAC2 directly. GST-HDAC1 and GST-HDAC2 proteins were purified from E. coli and the FLAG-Chfr proteins were purified from HEK293T cells. Purified FLAG-Chfr and GST-HDAC1, GST-HDAC2 or GST were incubated with glutathione Sepharose for 1 h at 4°C. Precipitates were subjected to SDS-PAGE followed by immunoblot with anti-FLAG or coomassie blue staining. (d) HEK293T cells were transiently transfected with pCMV-3xFLAG as a control and pCMV-3xFLAG-Chfr-I306A. Cell lysates (1 or 10 mg) were immunoprecipitated with anti-M2 resin. Proteins co-immunoprecipitated with Chfr were separated by SDS-PAGE, evaluated in parallel by immunoblotting with indicated antibodies. were increased upon silencing of Chfr, the levels of SIN3A were not changed. HEK293T cells were transfected with 2 µg of CHFR specific shRNA vector (shCHFR) or a negative control vector (shLuci). After incubation for 72 h, cell lysates were subjected to immunoblot with anti-HDAC1, anti-HDAC2 or anti-SIN3A antibodies. (c) The ubiquitination of endogenous HDAC1 was decreased in HEK293T cells depleted endogenous Chfr by RNAi. HEK293T cells were transfected with plasmids encoding HA-Ubiquitin, CHFR specific shRNA vector (shCHFR) or a negative control vector (shLuci). After incubation for 60 h, cells were treated with 2 µM MG132 for 12 h. Cell lysates were then immunoprecipitated with anti-HDAC1 and immunoblotted with indicated antibodies. 
